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Introduction: The local cytokine milieu of target organs is
poorly described in acute graft versus host disease (aGVHD)
or engraftment syndrome (ES). A novel and noninvasive
methodology using D-Squame (Cuderm Dallas, TX) skin
sampling discs was utilized to collect the superﬁcial layer of
the stratum corneum in patients with acute skin GVHD or ES
and cytokines were measured from the keratinocytes which
adhered to the disc.
Methods: D-squame skin sampling discs were placed on the
forearm/wrist of 13 pediatric patients (ages 0.25 years-14
years) for 2 minutes and removed. In patients with acute skin
GVHD or ES, samples were obtained from the involved area
of the forearm/wrist. This procedurewas noted to be painless
and safe even for young infants. Superﬁcial keratinocytes
were sampled by the fully cured medical grade polyacrylate
ester adhesive on the disc. Cytokines were extracted from the
sampling discs using a buffer made of phosphate buffered
saline and 0.25 molar saline and analyzed using a 38 plex
human cytokine Milliplex MAP magnetic bead panel (EMD
Millipore Corp, Billerica, MA). Patients were divided into 4
groups; acute skin GVHD (n¼5), isolated engraftment
syndrome (n¼2), no acute GVHD or ES (n¼2) and healthy
pediatric controls (n¼4).
Results: IL1a was elevated in patients with aGVHD as
compared to healthy controls and patients who did not
develop aGVHD or ES (P ¼ .02 and P ¼ .04) Similarly IL1a was
elevated in ES as compared to patients who did not develop
aGVHD/ESor tohealthypediatric controls (P¼ .05 andP¼ .01).
Conclusions: These preliminary results demonstrate a novel
methodology to measure inﬂammatory cytokines locally in
acute skin GVHD and ES. With further patients and analysis,
newapproaches tomanagementmaybeindicated inthe future.
Figure 1. Average values of IL1a measured from the epidermis in patients with
ES, aGVHD, no ES or aGVHD and healthy pediatric controls.Table I
Response to alemtuzumab
Patient Organ(s)
Involved
Grade at
Alemtuzumab
Administration
Grade
at Day
28
Stage at
Alemtuzuma
Administrati
1 Skin III 0 III
GI III
2 Skin III III I
GI IV
Liver II
3 Skin III III II
GI III
4 Skin IV IV II
Liver IV
5 GI III 0 IV445
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Introduction: No clear second line agent exists for the
treatment of steroid refractory acute graft versus host
disease (SR-aGVHD) in children. Alemtuzumab is associated
with partial or complete responses in 50-94% of adult
patients. Studies are lacking in pediatric patients. The
optimal dose for young patients is unknown. Here we
present the ﬁrst phase of a single center dose-escalation
study of alemtuzumab for treatment of acute SR-aGVHD in
pediatric patients.
Methods: Patients were prospectively enrolled at the time of
diagnosis of grades II-IV acute GVHD. Patients were initially
treated with 4mg/kg/day methylprednisolone. If patients
failed to improve within 5 days, or worsened within 48
hours, SR-aGVHD was diagnosed and alemtuzumab was
administered at 0.2 mg/kg/day for 5 consecutive days
(maximum cumulative dose of 31mg). Additional 0.2mg/kg
doses were given on days 15, 22 and 29 (maximum dose
10mg/dose). Patients were monitored weekly for response.
Partial response (PR) was deﬁned as improvement in stage of
GVHD before 28 days following ﬁrst alemtuzumab admin-
istration, and complete response (CR) was deﬁned as
achievement of grade zero GVHD by 28 days following the
ﬁrst alemtuzumab administration.
Results: Six patients have been enrolled and 5 patients with
grades III (n¼4) or IV (n¼1) GVHD were treated with alem-
tuzumab so far. Median age was 12 years (range 1.9-27
years). Organs involved included skin (n¼4), gastrointestinal
tract (n¼4) and liver (n¼2) (Table I). Forty percent of patients
(n¼2) had a CR. Sixty percent of patients (n¼3) had a PR.
Adverse effects included transient neutropenia or
thrombocytopenia (n¼3), fever (n¼2), or asymptomatic
EBV viremia (n¼2) and/or adenovirus viremia (n¼2).
Conclusion: Alemtuzumab is an active agent for the treat-
ment of SR-a GVHD in pediatric patients. Further dose
escalation may increase complete response rates and estab-
lish an optimal regimen for successful therapy.b
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I 0 0 0 0
III 0 0 0 0
0 0 0 0 0
III III III I II
II II II II II
I 0 End of study therapy
III III
I 0 End of study therapy
IV IV
I I I 0 0
